Effect of BET inhibition on CV outcomes in ACS and diabetes patients - PACE-CME

Effect of BET inhibition on CV outcomes in ACS and diabetes patients

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

What we can learn from registry data to improve lipid goal attainment
What we can learn from registry data to improve lipid goal attainment
Hyperlipidemia
What we can learn from registry data to improve lipid goal attainment
- Kausik Ray, MBChB, MD, MPhil
FCS and SHTG: Are We Meeting the Need?
FCS and SHTG: Are We Meeting the Need?
CME/CE
FCS and SHTG: Are We Meeting the Need?
0.25 credits
- Ira J. Goldberg, MD
- Kausik Ray, MBChB, MD, MPhil
- Christie Ballantyne
0.25 credits
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
AHA 2024
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
Early and sustained non-HDL-c target achievement after MI
Early and sustained non-HDL-c target achievement after MI
Hyperlipidemia
Early and sustained non-HDL-c target achievement after MI
- Jessica Schubert, MD